Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Erlotinib + Rilotumumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Erlotinib||Tarceva||CP358774||EGFR Inhibitor (Pan) 57 EGFR Inhibitor 1st gen 3||Tarceva (erlotinib) is a first-generation EGFR inhibitor that blocks EGFR signaling, potentially leading to inhibition of tumor growth (PMID: 30069756). Tarceva (erlotinib) is FDA approved for use in patients with non-small cell lung cancer harboring EGFR exon 19 deletions and/or EGFR L858R, and in combination with gemcitabine for patients with locally advanced, unresectable, or metastatic pancreatic cancer (FDA.gov).|
|Rilotumumab||AMG102|AMG-102||HGF Antibody 4||Rilotumumab (AMG-102) is a humanized monoclonal antibody directed against HGF, which interferes with the interaction between HGF and c-Met to prevent c-Met activation (PMID: 19649990, PMID: 31129386).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02154490||Phase II||Docetaxel Nivolumab Palbociclib Durvalumab Ipilimumab + Nivolumab AZD4547 Taselisib Durvalumab + Tremelimumab Erlotinib + Rilotumumab Talazoparib Erlotinib||Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer||Completed||USA | CAN||0|